Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diet and exercise may ease rare lung disease

NCT ID NCT03288025

Disease control Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a 12-week program of exercise and diet counseling can improve insulin sensitivity and heart function in people with pulmonary arterial hypertension (PAH). The 34 participants have stable PAH and are already on standard medications. The goal is to see if lifestyle changes can help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nutrition and exercise program
What this could lead to
If it works, this could point toward a non-drug way to help manage PAH symptoms and improve heart function.
What could go wrong
This is a small early trial with only 34 people, so results may not apply to everyone. Diet and exercise may not be enough to significantly change the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

34 people

The number who actually took part.

Started

Sep 2017

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age range between 18-75 years old * Group 1 PAH, including idiopathic, heritable, drugs and toxin induced, and PAH associated with connective tissue disease, HIV infection and congenital heart disease * NYHA Class II or III * ≥ 1 PAH-targeted therapy with a stable dose for ≥ 2 months * Stable dose of diuretics and rate of supplemental oxygen for the preceding 2 months Exclusion Criteria: * Decompensated Right Heart Failure * NYHA Class IV * Syncope within the previous 3 months * Cardiac Arrhythmia (except for controlled atrial fibrillation or flutter) * Baseline supplemental O2 \> 4 LPM * Portal Hypertension * Pulmonary hypertension due to Lung Disease and Hypoxia * Pulmonary Hypertension due to Left Heart Disease * Chronic Thromboembolic Pulmonary Hypertension * Pulmonary Hypertension associated with systemic diseases such as hematological disorders and sarcoidosis * Type 2 Diabetes * Evidence of cardiac ischemia on a graded exercise test

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulin resistance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Inflammation Insulin Resistance pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulin resistance Pulmonary arterial hypertension

Contacts and locations

Locations

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.